The U.S. Department of Energy’s Office of Science announced allocations of supercomputer access to 51 high-impact computational science projects for 2022 through its Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
The COHERENT particle physics experiment at the Department of Energy’s Oak Ridge National Laboratory has firmly established the existence of a new kind of neutrino interaction.
In the quest for advanced vehicles with higher energy efficiency and ultra-low emissions, ORNL researchers are accelerating a research engine that gives scientists and engineers an unprecedented view inside the atomic-level workings of combustion engines in real time.
Six scientists at the Department of Energy’s Oak Ridge National Laboratory were named Battelle Distinguished Inventors, in recognition of obtaining 14 or more patents during their careers at the lab.
Six ORNL scientists have been elected as fellows to the American Association for the Advancement of Science, or AAAS.
The annual Director's Awards recognized four individuals and teams including awards for leadership in quantum simulation development and application on high-performance computing platforms, and revolutionary advancements in the area of microbial
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.